← Home
Clinical Pearls & Perspectives
Practical Insights in Contemporary Cardiovascular Care
Short, practical clinical pearls on heart failure, cardiomyopathy, pulmonary hypertension, cardiogenic shock, emerging therapies and systems of care. Every pearl has its own page and shareable link.
Heart Failure Prevention
- Clinical PearlCCTA Is Changing How We Think About Coronary Artery DiseaseFor years, coronary risk assessment focused heavily on the coronary artery calcium (CAC) score. CAC remains an excellent, validated tool—but it tells us primarily about calcified plaque.
- PerspectiveCKM Staging: A Paradigm Shift in Cardiovascular CareThe new Cardiovascular-Kidney-Metabolic (CKM) staging framework from the ACC/AHA represents one of the most important shifts in cardiovascular medicine in decades.
- Clinical PearlStatins, Dementia, and the Patient Who Still Says “No”One of the most persistent concerns I hear from patients is: “I don’t want to take a statin because I’m worried about dementia.” Randomized trials, systematic reviews, and large observational studies have not demonstrated that statins cause dementia or progressive cognitive decline. And if a patient still refuses a statin, we now have more LDL-lowering alternatives than ever.
HFrEF
- Clinical PearlAmiodarone in Heart Failure: Are We Monitoring Enough?Amiodarone is frequently used in patients with heart failure—particularly when atrial or ventricular arrhythmias coexist with reduced EF. But prescribing amiodarone should probably come with something else: a monitoring plan.
- Clinical PearlShould Cardiac Rehabilitation Be Part of GDMT for Heart Failure?Cardiac rehabilitation (CR) is a structured program of supervised exercise, education, and lifestyle support that helps heart failure patients rebuild functional capacity and quality of life.
- Clinical PearlExternal Wearable Defibrillators (Vests) May Be Changing the ICD TimelineFor decades, patients with newly diagnosed HFrEF have faced a relatively rigid timeline: GDMT, reassess LV function after a defined waiting period, and if the EF remains severely reduced, consider a primary prevention ICD.
- Clinical PearlAFib Begets Heart Failure. Heart Failure Begets AFib.A vicious cycle. An opportunity to change the trajectory.
- PerspectiveAFib + CHF: Rate Control Won the Debate. Then Ablation Changed the Rules.Rhythm control may not have failed. The way we were achieving rhythm control may have failed.
- Clinical PearlPOCUS in the Difficult Heart Failure ExamPOCUS is changing how we assess congestion in heart failure.
HFpEF
- PerspectiveObesity and HFpEF: Transforming Care with Cardiometabolic TherapyHeart failure with preserved ejection fraction (HFpEF) remains one of the greatest challenges in cardiovascular medicine, and obesity is increasingly recognized as one of its most important drivers.
- Clinical PearlHFpEF Is Not One DiseaseHFpEF represents a heterogeneous syndrome. Obesity, hypertension, atrial fibrillation, renal disease, pulmonary hypertension, and metabolic dysfunction may drive very different phenotypes.
- Clinical Pearl“HFpEF Exacerbation”: Are We Looking Deeply Enough?Dyspnea. Edema. Weight gain. An EF of 60%. Too often, the admission diagnosis becomes automatic. But preserved LV EF does not tell us what is driving the congestion.
- PerspectiveHFpEF: The Diagnosis of (In)ConvenienceWhen dyspnea, edema, and volume overload become a lifelong heart failure diagnosis. HFpEF is increasingly used as a convenient explanation for symptoms that may have little to do with intrinsic left ventricular heart failure.
Right Heart Failure
- Clinical PearlWhen Is It Too Late to Fix the Tricuspid Valve in Right Ventricular Failure?As transcatheter tricuspid edge-to-edge repair (T-TEER) becomes more widely available, the key question is shifting. It's no longer just: How severe is the TR? It's: Can the right ventricle still recover if we fix it?
- Clinical PearlCardiac Cirrhosis: Are We Paying Enough Attention to the Liver in Heart Failure?We routinely follow kidney function in patients with heart failure. But how often do we look for the consequences of chronic hepatic congestion?
Shock & MCS
Cardiomyopathy
- Clinical PearlVUS, I Have a Beef With You!Variant of Uncertain Significance: Don’t Ignore It. Investigate It.
- Clinical PearlDynamic LVOT Obstruction: How Dynamic Is “Dynamic”? One Doppler Image Tells the StoryThis continuous-wave Doppler tracing beautifully demonstrates why LVOT obstruction in hypertrophic cardiomyopathy is called dynamic. During Valsalva, loading conditions change—and in this single continuous tracing, we can watch the LVOT Doppler envelope change with them.
- Clinical PearlBeyond the Ejection Fraction: The Role of Cardiac MRI in Heart FailureFor decades, much of heart failure imaging has revolved around a single number: the ejection fraction. But EF tells us how the heart is functioning—it does not necessarily tell us why it is failing. This is where cardiac MRI has changed the evaluation of heart failure.
- Clinical PearlAlcoholic Cardiomyopathy: When Is It Reversible?Alcoholic cardiomyopathy is an important reminder that a very low EF does not always mean permanent heart damage.
- Clinical PearlCardiomyopathy: To Exercise or Not to Exercise?For years, patients diagnosed with cardiomyopathy were often given a simple recommendation: 'Don't exercise.' That message is changing. For many patients with cardiomyopathy, exercise is not only possible—it can be beneficial. The key is determining the right type, the right amount, for the right person.
- Clinical PearlWhat if “Idiopathic” Cardiomyopathy Isn't Really Idiopathic?As genetic testing expands in dilated cardiomyopathy, TTN is becoming increasingly important. Genetics creates susceptibility. Environment may determine when—or whether—the disease emerges.
- PerspectiveHypertrophic Cardiomyopathy (HCM) Is Entering a New EraNot long ago, HCM management focused primarily on symptom control and preventing sudden cardiac death. Today, innovation is reshaping how we diagnose, risk-stratify, and treat this complex disease.
- PerspectiveSubstance Use Navigators: The Heroes Helping With Treatment of Methamphetamine Induced CardiomyopathyMethamphetamine induced cardiomyopathy is more than a heart failure diagnosis: it is a chronic disease at the intersection of cardiology, addiction medicine, mental health, and social determinants of health.
- Clinical PearlMethamphetamine Cardiomyopathy: Treatment Beyond GDMTHeart failure therapy is only part of the treatment strategy. Addressing the underlying substance-use disorder may be essential to long-term myocardial recovery.
Pulmonary Hypertension
- PerspectivePulmonary Hypertension: A Serious Disease That Is Too Often IgnoredPulmonary hypertension (PH) is not simply "high pressure in the lungs." It is a progressive disease that places tremendous strain on the right side of the heart and, if left untreated, can ultimately lead to right heart failure and premature death.
- Clinical PearlPulmonary Hypertension Is More Than an Elevated PA PressureAccurate classification requires attention to hemodynamics, right ventricular function, underlying disease, and the clinical context driving pulmonary vascular stress.
- Clinical PearlPAH: The Era of Four-Pathway Therapy?For years, pulmonary arterial hypertension treatment has focused on three pathways. Now there is a fourth—activin signaling—and the question is shifting from whether it belongs in the arsenal to how early we should use it.
Cardio-Oncology
Cardiac Devices
- PerspectiveBeyond the Four Pillars: Is Cardiac Modulation the Next Frontier in Heart Failure?Beyond GDMT’s four pillars, a different device approach is gaining attention: modulating cardiac physiology rather than replacing or mechanically supporting the failing heart.
- PerspectiveImplantable Remote Monitoring in Heart Failure: An Expanding FrontierHeart failure care is increasingly moving beyond the clinic visit. Innovation in implantable remote monitoring is creating new opportunities to follow physiology at home and recognize deterioration before it becomes a hospitalization.
- Clinical PearlTAVR, TEER, WATCHMAN: Who Needs Antibiotic Prophylaxis?As structural heart procedures become increasingly common, this question comes up frequently—especially before dental work. TAVR, TEER, or WATCHMAN: the answers are not all the same.
Heart Transplantation
Emerging Therapies
- Clinical PearlThe Next Frontier in Heart Failure: Decongestion at HomeFor decades, worsening congestion in CHF has followed a familiar pathway: oral diuretics → inadequate response → ED → IV diuretics → hospitalization. That pathway may be starting to change.
- PerspectiveAldosterone Synthase Inhibition: Beyond the Mineralocorticoid ReceptorMRAs have earned their place as a cornerstone of guideline-directed medical therapy by blocking the mineralocorticoid receptor. But as aldosterone synthase inhibitors emerge, they raise a compelling question: is blocking the receptor enough, or could suppressing aldosterone production itself produce different clinical effects?
- PerspectiveBeyond Pharmacologic GDMTDevice-based therapies such as cardiac contractility modulation, baroreflex activation therapy, and remote hemodynamic monitoring are expanding the treatment landscape in heart failure.
Systems of Care
- PerspectiveHeart Failure Care Is Never a One-Person Job: The Caregiver Needs a Care Team TooIn heart failure, we spend enormous amounts of time discussing GDMT, hemodynamics, devices, remote monitoring, LVADs, and transplantation. But another intervention quietly holds much of this together: social support.
- Clinical PearlShould Cardiac Rehabilitation Be Part of GDMT for Heart Failure?Cardiac rehabilitation (CR) is a structured program of supervised exercise, education, and lifestyle support that helps heart failure patients rebuild functional capacity and quality of life.
- PerspectivePalliative Care Isn't the End of Heart Failure Care. It's an Essential Part of It.One of the biggest misconceptions in cardiology is that palliative care is only for patients at the very end of life. I would argue the opposite.
- PerspectiveThe Missing Link in Heart Failure Care: Social WorkGreat CHF care treats the patient and the circumstances surrounding them.
- PerspectivePharmacy: The Key to GDMT SuccessPharmacy is one of the most powerful drivers of guideline-directed medical therapy success for patients hospitalized with heart failure.
- PerspectiveHeart Failure Outcomes Are Built Between HospitalizationsTransitions of care, medication access, early follow-up, multidisciplinary support, and patient education are critical components of a high-performing heart failure program.
- PerspectiveImplantable Remote Monitoring in Heart Failure: An Expanding FrontierHeart failure care is increasingly moving beyond the clinic visit. Innovation in implantable remote monitoring is creating new opportunities to follow physiology at home and recognize deterioration before it becomes a hospitalization.
- Clinical PearlShould We Routinely Measure AV Fistula Flow in Dialysis Patients With Heart Failure?In dialysis patients with heart failure, we routinely assess volume status, EF, pulmonary pressures, valves, and cardiac output. But how often do we ask: what is the flow through the AV fistula?